FRIDAY, JULY 13, 2018

Pfizer

235 E 42nd St
New York, NY 10017-5703

Pfizer News

Zithromax donations aid in fight against trachoma

Pfizer Inc., the International Trachoma Initiative, and the ICTC have donated the 500 millionth dose of Zithromax. Read More »

GSK, Pfizer finalize meningitis assets transaction

GlaxoSmithKline (GSK) and Pfizer recently announced that they have successfully finalized their transaction of Nimenrix and Mencevax, both of which are meningitis assets. Read More »

Pfizer receives clearance to acquire Hospira

Pharmaceutical company must divest itself of four U.S. sterile injectable assets before deal is done. Read More »

Pfizer launches Phase 2b trial of multi-antigen Staphylococcus aureus vaccine

Pfizer, Inc. said Tuesday it has enrolled its first patient in the company’s Phase 2b clinical trial for its investigational Staphylococcus aureus (S. aureus) multi-antigen vaccine (P-06290510) for adults having elective spinal fusion surgery. Read More »

Pfizer to buy meningitis vaccines from GlaxoSmithKline

Pfizer Inc. recently announced that it has made an agreement with GlaxoSmithKline to acquire Nimenrix and Mencevax vaccines for meningitis A, C, W135 and Y. Read More »

Tessier-Lavigne leaves Pfizer board for Denali post

Pfizer Inc. has announced Marc Tessier-Lavigne stepped down from the company’s board of directors Thursday. Read More »

Pfizer taps Jansen to lead R&D programs for vaccines

Kathrin U. Jansen is new senior vice president of the Vaccine Research and Development Unit Read More »

Dr. Charles Reay Mackay named chief scientific officer of Pfizer Inc.

Pfizer Inc. recently named Dr. Charles Reay Mackay as the new chief scientific officer of the company’s Inflammation and Immunology Research Unit. Read More »

Pfizer publishes pneumonia immunization trial results

Pfizer Inc. recently published its findings from the company’s Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA). Read More »

Pfizer gains EU approval for pneumococcal vaccine

The European Commission recently granted an expanded indication for Pfizer, Inc.'s Prevenar 13. Read More »

Serogroup B meningococcal vaccine recommended for at-risk groups

ACIP recommends that people at higher risk receive the serogroup B meningococcal vaccine. Read More »

Top-line results positive for Pfizer's TRUMENBA Phase 2 study

Pfizer, Inc. on Tuesday announced positive top-line results from a phase two study of TRUMENBA, a meningococcal group B vaccine, administered with U.S. Read More »

Pfizer obtains herpes vaccine candidate from Redvax

Pfizer recently announced that it has acquired a controlling interest in Redvax GmbH, a spin-off from Redbiotec AG, a Swiss biopharmaceutical company. Read More »

Meningococcal Group B vaccine is now FDA-approved and available

In a recent announcement, Pfizer Inc. confirmed that its Meningococcal Group B Vaccine, TRUMENBA® has been approved by the FDA and is now available to US health professionals for active vaccination. Read More »

Pfizer's new meningitis vaccine approved by FDA

The U.S. Read More »